Bottom line
Is BIPIX a good fund? The bottom line
BIPIX is a share class of Biotechnology Ultrasector Profund, a managed technology sector mutual fund from ProShares.
It charges 1.52% — about $152 a year on every $10,000 invested, more expensive than 85% of technology sector funds we track.
It returned −5.2% over one year, +6.1% a year over five years, +4.4% a year over ten (as of Dec 31, 2024, per its prospectus).
With $119 million in net assets and 159 holdings, its largest position is N/a (6.7%) and the top 10 make up 30.5% of the portfolio.
What to watch
- Expensive for its category (1.52%)
Updated Nov 19, 2026
What BIPIX invests in
Biotechnology UltraSector ProFund (the Fund) seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) of the daily performance of the S&P Biotechnology Select Industry Index (the Index).
The Fund invests in financial instruments that ProFund Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The Index is designed to measure the performance of biotechnology companies included in the S&P Total Market Index. The S&P Total Market Index is designed to track the broad equity market listed and domiciled in the U.S. The Index includes companies in the biotechnology sub-industry according to the Global Industry Classification Standard (GICS). These companies are then weighted using an equal weight methodology with liquidity adjustments. The Indexs composition and the assigned weights are reevaluated every September with additional weight adjustments in March, June, and December. The Index is constructed and maintained by S&P Dow Jones Indices LLC. More information about the Index can be found using the Bloomberg ticker symbol…
From the fund's prospectus (filed Nov 25, 2025).
BIPIX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| BIPIX | −5.2% | +6.1% | +4.4% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2024
What BIPIX costs
On a $10,000 investment, BIPIX's 1.52% expense ratio costs about $152 a year. The prospectus estimates $1,813 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
BIPIX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | N/a | 6.70% |
| 2 | N/a | 5.15% |
| 3 | N/a | 4.12% |
| 4 | N/a | 4.12% |
| 5 | N/a | 3.16% |
| 6 | Agpxx | 2.40% |
| 7 | Apogee Therapeutics Inc | 1.29% |
| 8 | N/a | 1.24% |
| 9 | Oruka Therapeutics Inc | 1.20% |
| 10 | Dianthus Therapeutics Inc | 1.12% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 30.5% of the fund. See all top 25 holdings and asset mix →